The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
ICMR will continue to track trends in HMPV circulation throughout the year
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Divestment is part of BASF’s strategic portfolio optimization
Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
Subscribe To Our Newsletter & Stay Updated
